Study: David 2025, Journal of the American Academy of Dermatology

A phase 2a trial of brepocitinib for cicatricial alopecia

Citation

David E, Shokrian N, Del Duca E, Meariman M et al (2025). Journal of the American Academy of Dermatology. PubMed id 39461505.

Open on PubMed

Cards that cite this study (1)

Each card gives its own wording for who was tested, how and what was found.

  • CCCA: scarring hair loss at the crown Tier B thin

    B Adults with lichen planopilaris, frontal fibrosing alopecia or central centrifugal cicatricial alopecia (how many had CCCA is not stated in the abstract) (n=not stated in the abstract)

    Randomised, placebo-controlled phase 2a trial, 3:1 to brepocitinib 45 mg daily or placebo for 24 weeks, then all on drug to 48 weeks.

    Brepocitinib significantly lowered lesional CCL5 expression at week 24 (P=.004), was well tolerated and improved clinical severity scores. Coprimary endpoints were biomarkers and safety, not hair regrowth. The authors list a single dose and a small placebo group as limitations.

    As recorded in this card: David E, Shokrian N, Del Duca E, Meariman M et al (2025), Journal of the American Academy of Dermatology, [primary]

    Note: Mixed scarring alopecias, an experimental drug, biomarker endpoints; not evidence about what to do for CCCA today. Added after the 12 Nov fact-check search.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.